Allarity Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALLR Nasdaq 2836 www.allarity.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allarity Therapeutics, Inc.

Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025 - Apr 25th, 2025 12:00 pm
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - Mar 31st, 2025 8:05 pm
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - Mar 24th, 2025 12:00 pm
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - Mar 17th, 2025 12:00 pm
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - Mar 13th, 2025 12:30 pm
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - Mar 6th, 2025 1:00 pm
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program - Mar 3rd, 2025 1:00 pm
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit - Feb 26th, 2025 1:00 pm
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients - Feb 24th, 2025 1:00 pm
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer - Feb 6th, 2025 1:00 pm
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC - Jan 30th, 2025 1:00 pm
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - Nov 18th, 2024 1:00 pm
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights - Nov 14th, 2024 1:00 pm
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib - Oct 22nd, 2024 12:00 pm
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement - Oct 10th, 2024 12:00 pm
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program - Oct 3rd, 2024 12:00 pm
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial - Sep 16th, 2024 12:00 pm
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 13th, 2024 12:45 pm
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) - Sep 11th, 2024 12:00 pm
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting - Jul 26th, 2024 1:00 pm